Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

被引：1

作者：

Shah, Jatin J. ^{[1
]}

Feng, Lei ^{[1
]}

Manasanch, Elisabet E. ^{[1
]}

Weber, Donna M. ^{[1
]}

Thomas, Sheeba K. ^{[1
]}

Turturro, Francesco ^{[1
]}

Alexanian, Raymond ^{[1
]}

Shah, Nina ^{[1
]}

Popat, Uday R. ^{[1
]}

Nieto, Yago ^{[1
]}

Bashir, Qaiser ^{[1
]}

Qazilbash, Muzaffar H. ^{[1
]}

Champlin, Richard E. ^{[2
]}

Orlowski, Robert Z. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2020, 136
[22] Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph, Nisha S.
Kaufman, Jonathan L.
Dicamillo, Sara
Roberts, Danielle
Gupta, Vikas A.
Hofmeister, Craig C.
Dhodapkar, Madhav V.
Boise, Lawrence H.
Lonial, Sagar
Nooka, Ajay K.
BLOOD, 2023, 142
[23] MAINTENANCE THERAPY WITH BORTEZOMIB/DEXAMETHASONE IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS CARRYING HIGH RISK FEATURES
Mancuso, K.
Tacchetti, P.
Pantani, L.
Rocchi, S.
Rizzello, I.
Caratozzolo, I.
De Cicco, G.
Fusco, A.
Testoni, N.
Terragna, C.
Marzocchi, G.
Martello, M.
Borsi, E.
Dozza, L.
Zamagni, E.
Cavo, M.
HAEMATOLOGICA, 2019, 104 : 50 - 50
[24] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis
Chari, Ajai
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Ander J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S31 - S31
[25] Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study
Sonneveld, Pieter
Dimopoulos, Meletios
Boccadoro, Mario
Hang Quach
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels
Liu, Yanfang
Wang, Jianping
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Rodriguez-Otero, Paula
Blade, Joan
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S246 - S246
[26] Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
Rosinol, Laura
Hebraud, Benjamin
Oriol, Albert
Colin, Anne-Laurene
Tamayo, Rafael Rios
Hulin, Cyrille
Blanchard, Maria Jesus
Caillot, Denis
Sureda, Anna
Hernandez, Miguel Teodoro
Arnulf, Bertrand
Mateos, Maria-Victoria
Macro, Margaret
San-Miguel, Jesus
Belhadj, Karim
Lahuerta, Juan Jose
Garelik, M. Brigid
Blade, Joan
Moreau, Philippe
FRONTIERS IN ONCOLOGY, 2023, 13
[27] Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients
Joseph, Nisha
Gupta, Vikas A.
Hofmeister, Craig C.
Gleason, Charise
Heffner, Leonard
Boise, Lawrence H.
Kaufman, Jonathan L.
Dhodapkar, Madhav V.
Lonial, Sagar
Nooka, Ajay K.
BLOOD, 2018, 132
[28] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Shune, Leyla
Badros, Ashraf
Chari, Ajai
Richardson, Paul G.
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Hoehn, Daniela
Lin, Thomas S.
Voorhees, Peter M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309
[29] Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial
Muranushi, Hiroyuki
Kanda, Junya
Kobayashi, Masayuki
Maeda, Takeshi
Kitano, Toshiyuki
Tsuji, Masaaki
Ueda, Yasunori
Ishikawa, Takayuki
Nohgawa, Masaharu
Watanabe, Mitsumasa
Imada, Kazunori
Moriguchi, Toshinori
Itoh, Mitsuru
Ohno, Hitoshi
Yonezawa, Akihito
Hirata, Hirokazu
Arima, Nobuyoshi
Asagoe, Kohsuke
Anzai, Naoyuki
Nagata, Kayoko
Yasuno, Shinji
Kuwabara, Yoshihiro
Kitao, Hiromi
Kim, Ihhwa
Kawagishi, Kiyomi
Ueshima, Kenji
Tominari, Shinjiro
Nakayama, Takeo
Yamashita, Kouhei
Takaori-Kondo, Akifumi
HEMATOLOGY, 2022, 27 (01) : 239 - 248
[30] Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma
Moreau, Philippe
Giralt, Sergio A.
LEUKEMIA RESEARCH, 2012, 36 : S13 - S18

← 1 2 3 4 5 →